[go: up one dir, main page]

MX2016011580A - Dominios de fibronectina tipo iii que se unen a albumina de suero. - Google Patents

Dominios de fibronectina tipo iii que se unen a albumina de suero.

Info

Publication number
MX2016011580A
MX2016011580A MX2016011580A MX2016011580A MX2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A
Authority
MX
Mexico
Prior art keywords
serum albumin
type iii
domains
fibronectine
join
Prior art date
Application number
MX2016011580A
Other languages
English (en)
Other versions
MX378753B (es
Inventor
Lipovsek Dasa
L Gosselin Michael
Fabrizio David
Camphausen Ray
S Mitchell Tracy
PARKER Rex
Davis Jonathan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016011580A publication Critical patent/MX2016011580A/es
Publication of MX378753B publication Critical patent/MX378753B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a polipéptidos los cuales incluyen el décimo dominio de fibronectina tipo III (10Fn3) que se une a albúmina de suero, con sustituciones del bucle del polo sur. La invención, además, se refiere a moléculas de fusión que comprenden un 10Fn3 de unión a albúmina de suero unido a una proteína heteróloga para uso en aplicaciones de diagnóstico y terapéuticas.
MX2016011580A 2014-03-20 2015-03-19 Dominios de fibronectina tipo iii que se unen a albúmina de suero. MX378753B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968181P 2014-03-20 2014-03-20
PCT/US2015/021535 WO2015143199A1 (en) 2014-03-20 2015-03-19 Serum albumin-binding fibronectin type iii domains

Publications (2)

Publication Number Publication Date
MX2016011580A true MX2016011580A (es) 2016-11-29
MX378753B MX378753B (es) 2025-03-10

Family

ID=52808189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011580A MX378753B (es) 2014-03-20 2015-03-19 Dominios de fibronectina tipo iii que se unen a albúmina de suero.

Country Status (14)

Country Link
US (3) US10442851B2 (es)
EP (2) EP3129401B1 (es)
JP (2) JP6591437B2 (es)
KR (2) KR102472862B1 (es)
CN (2) CN106170494B (es)
AU (1) AU2015231170B2 (es)
CA (1) CA2943241C (es)
EA (2) EA202090216A3 (es)
ES (2) ES2913840T3 (es)
IL (2) IL275497B (es)
MX (1) MX378753B (es)
SG (1) SG11201607820QA (es)
WO (1) WO2015143199A1 (es)
ZA (1) ZA201606321B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
SG11201607820QA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
AU2015353573B2 (en) 2014-11-25 2020-09-03 Bristol-Myers Squibb Company Novel PD-L1 binding polypeptides for imaging
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
JP7189767B2 (ja) * 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
SG11201810687SA (en) * 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
AU2017357931B2 (en) 2016-11-10 2024-12-05 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
RU2759952C2 (ru) 2016-12-14 2021-11-19 Янссен Байотек, Инк. Cd8a-связывающие домены типа iii фибронектина
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
SG11202011308VA (en) * 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
CN120643704A (zh) 2018-05-16 2025-09-16 Lib疗法股份有限公司 包含结合pcsk9的分子的组合物和使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CA3161723A1 (en) 2019-12-18 2021-06-24 Karyn O'neil Serum albumin-binding fibronectin type iii domains and uses thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN112067806A (zh) * 2020-09-25 2020-12-11 徐州医科大学 Caspase-1在制备提高CAR-T治疗效果的药物中的应用
KR102284800B1 (ko) * 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
US20240316154A1 (en) * 2021-02-02 2024-09-26 Eli Lilly And Company Half-life extending moieties and methods of using the same
KR20240034160A (ko) 2021-04-14 2024-03-13 에이알오 바이오테라퓨틱스 컴패니 Cd71 결합 피브로넥틴 3형 도메인
AU2022258584A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4330383A1 (en) * 2021-04-29 2024-03-06 Novartis AG Hypersialylating cells
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CN114790473B (zh) * 2021-11-08 2025-01-28 汉肽生物医药集团有限公司 一种利拉鲁肽融合蛋白在位酶切和纯化的方法
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
CN115386009B (zh) * 2022-04-26 2023-12-01 江苏靶标生物医药研究所有限公司 一种膜联蛋白v与血管生成抑制剂融合蛋白的构建方法和应用
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
TW202432577A (zh) * 2023-02-10 2024-08-16 美商拜奧海芬治療學有限公司 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
FR3147292A1 (fr) 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
CN121013863A (zh) 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 Tnfr2结合多肽及使用方法

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5773574A (en) 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
WO1993003172A1 (en) 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5559000A (en) 1995-01-18 1996-09-24 The Scripps Research Institute Encoded reaction cassette
DE19646372C1 (de) 1995-11-11 1997-06-19 Evotec Biosystems Gmbh Genotyp und Phänotyp koppelnde Verbindung
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
EP0962527B1 (en) 1996-10-17 2004-08-04 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
RU2233878C2 (ru) 1997-01-21 2004-08-10 Дзе Дженерал Хоспитал Корпорейшн Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
ES2383332T3 (es) 1999-07-27 2012-06-20 Bristol-Myers Squibb Company Procedimiento de ligación de aceptores de péptidos
WO2001072829A2 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
JP2004515219A (ja) 2000-06-15 2004-05-27 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 調節可能な触媒活性な核酸
EP2385067A1 (en) 2000-07-11 2011-11-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
AU2002307146B2 (en) 2001-04-04 2007-02-01 University Of Rochester AlphaNuBeta3 integrin-binding polypeptide monobodies and their use
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
AU2002342672A1 (en) 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
MXPA06006406A (es) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AP2008004418A0 (en) 2005-10-07 2008-04-30 Univ California Nucleic acids encoding modified cytochrome p450 enzyme and methods of use thereof
PT1973559E (pt) 2005-11-23 2013-02-19 Acceleron Pharma Inc Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo
AU2007218318A1 (en) 2006-02-24 2007-08-30 Chiesi Farmaceutici S.P.A. Anti-amyloid immunogenic compositions, methods and uses
WO2007121894A2 (en) 2006-04-21 2007-11-01 Transgene S.A. Hpv-18-based papillomavirus vaccine
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
JP2010507099A (ja) 2006-10-16 2010-03-04 ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー 合成抗体
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EP2197476A2 (en) 2007-08-20 2010-06-23 Bristol-Myers Squibb Company Use of vegfr-2 inhibitors for treating metastatic cancer
BRPI0818810A2 (pt) 2007-10-31 2014-10-29 Medimmune Llc Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
WO2009073115A1 (en) 2007-11-28 2009-06-11 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
AU2008345674A1 (en) 2007-12-19 2009-07-09 Centocor, Ortho Biotech Inc. Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage
BRPI0821924A2 (pt) * 2007-12-27 2015-07-07 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e seu uso
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
AT506740B1 (de) 2008-04-16 2010-07-15 Haas Franz Waffel & Keksanlagen Industrie Gmbh Anlage zum herstellen von sandwichkeksen und dergleichen
JP6192891B2 (ja) * 2008-05-02 2017-09-06 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
EP3128048B1 (en) 2008-10-31 2018-11-28 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR20110104052A (ko) 2008-12-16 2011-09-21 노파르티스 아게 효모 디스플레이 시스템
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2011103105A1 (en) * 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
MX2012011781A (es) * 2010-04-13 2012-11-16 Squibb Bristol Myers Co Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9).
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
RU2767543C2 (ru) 2010-04-30 2022-03-17 Янссен Байотек, Инк. Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库
US9260496B2 (en) 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
ES2676499T3 (es) 2011-04-13 2018-07-20 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012158739A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
CN103827361A (zh) 2011-09-27 2014-05-28 詹森生物科技公司 具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
AU2013315482B2 (en) 2012-09-13 2018-03-15 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
EP2968587A2 (en) * 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
SG11201607820QA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains
ES2898273T3 (es) 2014-03-20 2022-03-04 Bristol Myers Squibb Co Moléculas con una estructura a base de fibronectina estabilizada
WO2017053617A1 (en) * 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains

Also Published As

Publication number Publication date
WO2015143199A1 (en) 2015-09-24
IL247825B (en) 2020-07-30
EP3572424A1 (en) 2019-11-27
BR112016020175A2 (pt) 2017-10-17
CA2943241A1 (en) 2015-09-24
EP3129401A1 (en) 2017-02-15
CN106170494A (zh) 2016-11-30
JP2017512469A (ja) 2017-05-25
EA034886B1 (ru) 2020-04-02
KR20160135762A (ko) 2016-11-28
EP3572424B1 (en) 2022-04-20
KR102472862B1 (ko) 2022-12-05
CN113150117A (zh) 2021-07-23
JP2020010705A (ja) 2020-01-23
EA201691669A1 (ru) 2017-01-30
EA202090216A2 (ru) 2020-05-31
CN106170494B (zh) 2021-04-09
US20170174748A1 (en) 2017-06-22
ES2913840T3 (es) 2022-06-06
KR20220162886A (ko) 2022-12-08
ZA201606321B (en) 2024-11-27
CA2943241C (en) 2023-09-19
ES2736127T3 (es) 2019-12-26
AU2015231170A1 (en) 2016-09-22
US11203630B2 (en) 2021-12-21
JP6591437B2 (ja) 2019-10-16
AU2015231170B2 (en) 2019-10-03
SG11201607820QA (en) 2016-10-28
JP7132898B2 (ja) 2022-09-07
US10442851B2 (en) 2019-10-15
US20200048328A1 (en) 2020-02-13
CN113150117B (zh) 2025-06-06
EP3129401B1 (en) 2019-06-12
US20220204589A1 (en) 2022-06-30
IL275497B (en) 2022-09-01
MX378753B (es) 2025-03-10
US12534511B2 (en) 2026-01-27
EA202090216A3 (ru) 2020-07-31
IL247825A0 (en) 2016-11-30
IL275497A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
MX2017006866A (es) Pares de unión para producción de péptidos.
CO6630173A2 (es) Moléculas de unión a seroalbuminae
DK3583125T3 (da) Albuminbindende domænefusionsproteiner
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
EA201892796A1 (ru) Связывающиеся с сывороточным альбумином домены фибронектина типа iii
EA201600141A1 (ru) Терапевтический слитый белок
MX2016011665A (es) Metodo para conexion de componentes, uno de los cuales consiste de plastico reforzado con fibra.
BR112016022841A2 (pt) cadeia j modificada
EP3188758C0 (en) SIRP ALPHA-ANTIBODY FUSION PROTEIN
PH12015502125A1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
MX2017001712A (es) Proteinas de fusion de inmunoglobulina de la proteina alfa reguladora de señal (sirp-alfa).
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
IL264151A (en) Fusion proteins have an extended half-life
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
IL271268A (en) A fusion protein that extends half-life
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков